Recursion Pharmaceuticals
RXRX
128 hedge funds and large institutions have $680M invested in Recursion Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 40 increasing their positions, 37 reducing their positions, and 21 closing their positions.
15% more call options, than puts
Call options by funds: $321K | Put options by funds: $278K
14% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 21
2% more funds holding
Funds holding: 126 → 128 (+2)
8% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 37
0.39% less ownership
Funds ownership: 59.14% → 58.75% (-0.39%)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
58% less capital invested
Capital invested by funds: $1.62B → $680M (-$936M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$7.55M |
| 2 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$7.36M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$7.05M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.54M |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$6.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$29.1M |
| 2 |
PC
PointState Capital
New York
|
-$7.02M |
| 3 |
BAMCO Inc
New York
|
-$7M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$6.32M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.14M |
RXRX Hedge Fund Activity: Q1 2022 in Review
128 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q1 2022, worth a combined $680M — down 58% from $1.62B a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new RXRX positions and 21 closed out — a net gain of 3 holders — while 40 added to existing stakes and 37 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $7.55M. The largest seller was State Street, cutting an estimated $29.1M.
- 128 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q1 2022, up from 126 in Q4 2021.
- Funds reported $680M of Recursion Pharmaceuticals stock for Q1 2022, down 58% quarter-over-quarter.
- 24 funds opened new Recursion Pharmaceuticals positions in Q1 2022 and 21 closed out, a net change of +3 holders.
- The largest Recursion Pharmaceuticals buyer in Q1 2022 was Citadel Advisors, an estimated $7.55M added.
- The largest Recursion Pharmaceuticals seller in Q1 2022 was State Street, an estimated $29.1M sold.
Based on aggregated 13F filings for Q1 2022.